These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 36218067)

  • 1. Exploiting Ligand-binding Domain Dimerization for Development of Novel Androgen Receptor Inhibitors.
    Helsen C; Nguyen TT; Lee XY; Eerlings R; Louros N; Schymkowitz J; Rousseau F; Claessens F; Voet A
    Mol Cancer Ther; 2022 Dec; 21(12):1823-1834. PubMed ID: 36218067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cryptotanshinone suppresses androgen receptor-mediated growth in androgen dependent and castration resistant prostate cancer cells.
    Xu D; Lin TH; Li S; Da J; Wen XQ; Ding J; Chang C; Yeh S
    Cancer Lett; 2012 Mar; 316(1):11-22. PubMed ID: 22154085
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antagonistic action of a synthetic androgen ligand mediated by chromatin remodeling in a human prostate cancer cell line.
    Sawada T; Kanemoto Y; Amano R; Hayakawa A; Kurokawa T; Mori J; Kato S
    Biochem Biophys Res Commun; 2022 Jul; 612():110-118. PubMed ID: 35523048
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selectively targeting the dimerization interface of human androgen receptor with small-molecules to treat castration-resistant prostate cancer.
    Dalal K; Ban F; Li H; Morin H; Roshan-Moniri M; Tam KJ; Shepherd A; Sharma A; Peacock J; Carlson ML; LeBlanc E; Perez C; Duong F; Ong CJ; Rennie PS; Cherkasov A
    Cancer Lett; 2018 Nov; 437():35-43. PubMed ID: 30165195
    [TBL] [Abstract][Full Text] [Related]  

  • 5. (+)-JJ-74-138 is a Novel Noncompetitive Androgen Receptor Antagonist.
    Cole RN; Chen W; Pascal LE; Nelson JB; Wipf P; Wang Z
    Mol Cancer Ther; 2022 Apr; 21(4):483-492. PubMed ID: 35058329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prx1 enhances androgen receptor function in prostate cancer cells by increasing receptor affinity to dihydrotestosterone.
    Chhipa RR; Lee KS; Onate S; Wu Y; Ip C
    Mol Cancer Res; 2009 Sep; 7(9):1543-52. PubMed ID: 19737972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel Inhibitors of androgen receptor's DNA binding domain identified using an ultra-large virtual screening.
    Radaeva M; Morin H; Pandey M; Ban F; Guo M; LeBlanc E; Lallous N; Cherkasov A
    Mol Inform; 2023 Aug; 42(8-9):e2300026. PubMed ID: 37193651
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of a Novel Androgen Receptor Antagonist Manifesting Evidence to Disrupt the Dimerization of the Ligand-Binding Domain via Attenuating the Hydrogen-Bonding Network Between the Two Monomers.
    Fu W; Zhang M; Liao J; Tang Q; Lei Y; Gong Z; Shan L; Duan M; Chai X; Pang J; Tang C; Wang X; Xu X; Li D; Sheng R; Hou T
    J Med Chem; 2021 Dec; 64(23):17221-17238. PubMed ID: 34809430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conformational dynamics of androgen receptors bound to agonists and antagonists.
    Gim HJ; Park J; Jung ME; Houk KN
    Sci Rep; 2021 Aug; 11(1):15887. PubMed ID: 34354111
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selectively targeting the DNA-binding domain of the androgen receptor as a prospective therapy for prostate cancer.
    Dalal K; Roshan-Moniri M; Sharma A; Li H; Ban F; Hessein M; Hsing M; Singh K; LeBlanc E; Dehm S; Tomlinson Guns ES; Cherkasov A; Rennie PS
    J Biol Chem; 2014 Sep; 289(38):26417-26429. PubMed ID: 25086042
    [TBL] [Abstract][Full Text] [Related]  

  • 11. "True" antiandrogens-selective non-ligand-binding pocket disruptors of androgen receptor-coactivator interactions: novel tools for prostate cancer.
    Caboni L; Kinsella GK; Blanco F; Fayne D; Jagoe WN; Carr M; Williams DC; Meegan MJ; Lloyd DG
    J Med Chem; 2012 Feb; 55(4):1635-44. PubMed ID: 22280402
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sensitization of androgen refractory prostate cancer cells to anti-androgens through re-expression of epigenetically repressed androgen receptor - Synergistic action of quercetin and curcumin.
    Sharma V; Kumar L; Mohanty SK; Maikhuri JP; Rajender S; Gupta G
    Mol Cell Endocrinol; 2016 Aug; 431():12-23. PubMed ID: 27132804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiandrogenic effects of novel androgen synthesis inhibitors on hormone-dependent prostate cancer.
    Long BJ; Grigoryev DN; Nnane IP; Liu Y; Ling YZ; Brodie AM
    Cancer Res; 2000 Dec; 60(23):6630-40. PubMed ID: 11118046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The androgen receptor T877A mutant recruits LXXLL and FXXLF peptides differently than wild-type androgen receptor in a time-resolved fluorescence resonance energy transfer assay.
    Ozers MS; Marks BD; Gowda K; Kupcho KR; Ervin KM; De Rosier T; Qadir N; Eliason HC; Riddle SM; Shekhani MS
    Biochemistry; 2007 Jan; 46(3):683-95. PubMed ID: 17223690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dihydrotestosterone-based A-ring-fused pyridines: Microwave-assisted synthesis and biological evaluation in prostate cancer cells compared to structurally related quinolines.
    Kiss MA; Peřina M; Bereczki L; Baji Á; Bělíček J; Jorda R; Frank É
    J Steroid Biochem Mol Biol; 2023 Jul; 231():106315. PubMed ID: 37086925
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201).
    Borgmann H; Lallous N; Ozistanbullu D; Beraldi E; Paul N; Dalal K; Fazli L; Haferkamp A; Lejeune P; Cherkasov A; Gleave ME
    Eur Urol; 2018 Jan; 73(1):4-8. PubMed ID: 28851578
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EPI-001 is a selective peroxisome proliferator-activated receptor-gamma modulator with inhibitory effects on androgen receptor expression and activity in prostate cancer.
    Brand LJ; Olson ME; Ravindranathan P; Guo H; Kempema AM; Andrews TE; Chen X; Raj GV; Harki DA; Dehm SM
    Oncotarget; 2015 Feb; 6(6):3811-24. PubMed ID: 25669987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional in vivo interaction between the amino-terminal, transactivation domain and the ligand binding domain of the androgen receptor.
    Doesburg P; Kuil CW; Berrevoets CA; Steketee K; Faber PW; Mulder E; Brinkmann AO; Trapman J
    Biochemistry; 1997 Feb; 36(5):1052-64. PubMed ID: 9033395
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Androgen receptor modulators: a review of recent patents and reports (2012-2018).
    Fujii S; Kagechika H
    Expert Opin Ther Pat; 2019 Jun; 29(6):439-453. PubMed ID: 31092069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of Novel Inhibitors Targeting the D-Box of the DNA Binding Domain of Androgen Receptor.
    Radaeva M; Ban F; Zhang F; LeBlanc E; Lallous N; Rennie PS; Gleave ME; Cherkasov A
    Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33801338
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.